| 2021 | Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer | LUNG CANCER |
| 2021 | The promise of bispecific antibodies: Clinical applications and challenges | CANCER TREATMENT REVIEWS |
| 2021 | Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
| CLINICAL CANCER RESEARCH |
| 2021 | Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
| CLINICAL LUNG CANCER |
| 2021 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study | LANCET ONCOLOGY |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2021 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target? | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2021 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients
| SCIENTIFIC REPORTS |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2020 | Preface | Memo |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
| 2020 | First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
| EUROPEAN JOURNAL OF CANCER |
| 2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
| 2020 | Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
| CANCER RESEARCH AND TREATMENT |
| 2020 | A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy | ANNALS OF ONCOLOGY |
| 2020 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer | EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2020 | Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
| LUNG CANCER |
| 2020 | Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC | CANCER DISCOVERY |
| 2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade | JCI INSIGHT |
| 2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial | ANNALS OF ONCOLOGY |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
| 2020 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial | JAMA ONCOLOGY |
| 2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
| 2020 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
| BMC CANCER |
| 2020 | Prognostic Implications of Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Amplification and Protein Overexpression in Hypopharyngeal and Laryngeal Squamous Cell Carcinoma
| BMC CANCER |
| 2020 | Osimertinib Plus Savolitinib in Patients With EGFR Mutation-Positive, MET-amplified, Non-Small-Cell Lung Cancer After Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results From a Multicentre, Open-Label, Phase 1b Study | LANCET ONCOLOGY |
| 2020 | Real-world Use of Osimertinib in Non-Small Cell Lung Cancer: ASTRIS Study Korean Subgroup Analysis | CURRENT MEDICAL RESEARCH AND OPINION |
| 2020 | Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study | CLINICAL LUNG CANCER |
| 2020 | Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
| EUROPEAN JOURNAL OF CANCER |
| 2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2019 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | LANCET ONCOLOGY |
| 2019 | Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC study | ANNALS OF ONCOLOGY |
| 2019 | Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis | ANTICANCER RESEARCH |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
http://orcid.org/0000-0002-5562-270X
(7401747804)
